Illumina, Inc.

NasdaqGS:ILMN Stock Report

Market Cap: US$21.6b

Illumina Past Earnings Performance

Past criteria checks 4/6

Illumina's earnings have been declining at an average annual rate of -18.9%, while the Life Sciences industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 3.4% per year. Illumina's return on equity is 29.5%, and it has net margins of 16.4%.

Key information

-18.87%

Earnings growth rate

-19.31%

EPS growth rate

Life Sciences Industry Growth21.51%
Revenue growth rate3.42%
Return on equity29.53%
Net Margin16.39%
Last Earnings Update28 Sep 2025

Recent past performance updates

Illumina (NASDAQ:ILMN) Strong Profits May Be Masking Some Underlying Issues

Aug 08
Illumina (NASDAQ:ILMN) Strong Profits May Be Masking Some Underlying Issues

Recent updates

Illumina, Inc. (NASDAQ:ILMN) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected

Nov 09
Illumina, Inc. (NASDAQ:ILMN) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected

Illumina: An Excellent Profit Margin And The Sequencing Genome Market Will Unlock Value

Nov 07

Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Aug 31
Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) Strong Profits May Be Masking Some Underlying Issues

Aug 08
Illumina (NASDAQ:ILMN) Strong Profits May Be Masking Some Underlying Issues

Illumina, Inc. Just Recorded A 76% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 05
Illumina, Inc. Just Recorded A 76% EPS Beat: Here's What Analysts Are Forecasting Next

Illumina, Inc.'s (NASDAQ:ILMN) Shareholders Might Be Looking For Exit

Jul 09
Illumina, Inc.'s (NASDAQ:ILMN) Shareholders Might Be Looking For Exit

These 4 Measures Indicate That Illumina (NASDAQ:ILMN) Is Using Debt Reasonably Well

Jun 13
These 4 Measures Indicate That Illumina (NASDAQ:ILMN) Is Using Debt Reasonably Well

Illumina, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 13
Illumina, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Is Illumina Undervalued After An 83% Drop In Its Stock Price?

Mar 27

Risks Still Elevated At These Prices As Illumina, Inc. (NASDAQ:ILMN) Shares Dive 35%

Mar 06
Risks Still Elevated At These Prices As Illumina, Inc. (NASDAQ:ILMN) Shares Dive 35%

Illumina: Navigating Headwinds As China Bans Instruments And Roche Enters The NGS Race

Mar 05

Illumina (NASDAQ:ILMN) Seems To Use Debt Quite Sensibly

Feb 07
Illumina (NASDAQ:ILMN) Seems To Use Debt Quite Sensibly

Illumina, Inc.'s (NASDAQ:ILMN) Price Is Out Of Tune With Revenues

Jan 20
Illumina, Inc.'s (NASDAQ:ILMN) Price Is Out Of Tune With Revenues

Illumina And Grail In 2025? Grounds For Optimism, If Mistakes Aren't Repeated

Dec 19

Illumina: Q3 Confirms Improving Fundamentals

Nov 05

Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)

Aug 21

Illumina: Strengthening Competitive Position, Relevance And A Very Compelling Valuation

Jul 23

Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out

Jun 28

Illumina: Expect A Slow Rebound

May 07

Revenue & Expenses Breakdown

How Illumina makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:ILMN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
28 Sep 254,2887031,103870
29 Jun 254,2841,2571,101893
30 Mar 254,337-9661,266971
29 Dec 244,372-1,2231,3941,068
29 Sep 244,390-1,5851,6411,118
30 Jun 244,429-3,0441,6311,180
31 Mar 244,493-1,2901,6291,204
31 Dec 234,504-1,1611,6201,207
01 Oct 234,465-1,1251,5721,234
02 Jul 234,461-4,1861,6771,246
02 Apr 234,448-4,4871,6361,227
01 Jan 234,584-4,4041,6141,209
02 Oct 224,700-4,1531,6821,242
03 Jul 224,693-201,5101,187
03 Apr 224,6567011,5501,061
02 Jan 224,5267621,744914
03 Oct 214,2809071,351794
04 Jul 213,9667691,350696
04 Apr 213,4736301,114650
03 Jan 213,2396561,014609
27 Sep 203,238638813572
28 Jun 203,351693811551
29 Mar 203,556942835562
29 Dec 193,5431,002907575
29 Sep 193,458973874607
30 Jun 193,405938881615
31 Mar 193,397851877600
30 Dec 183,333826849568
30 Sep 183,243684798538
01 Jul 183,103648768513
01 Apr 182,936567732492
31 Dec 172,752725720500
01 Oct 172,594775692488
02 Jul 172,487741664480
02 Apr 172,424730652474
01 Jan 172,398454630458
02 Oct 162,371440624450
03 Jul 162,314430621423
03 Apr 162,253415597395
03 Jan 162,220462561362
27 Sep 152,141510533348
28 Jun 152,071486516334
29 Mar 151,979430506321

Quality Earnings: ILMN has high quality earnings.

Growing Profit Margin: ILMN became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ILMN has become profitable over the past 5 years, growing earnings by -18.9% per year.

Accelerating Growth: ILMN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ILMN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (-0.2%).

Return on Equity

High ROE: ILMN's Return on Equity (29.5%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/06 10:16
End of Day Share Price 2026/01/05 00:00
Earnings2025/09/28
Annual Earnings2024/12/29

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Illumina, Inc. is covered by 44 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Catherine Ramsey SchulteBaird
Charles ButlerBarclays